Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9BYV8

UPID:
CEP41_HUMAN

ALTERNATIVE NAMES:
Testis-specific gene A14 protein

ALTERNATIVE UPACC:
Q9BYV8; A4D1M0; B4DQ35; F5H0V6; Q7Z496; Q86TM1; Q8NFU8; Q9H6A3; Q9NPV3

BACKGROUND:
Centrosomal protein of 41 kDa, alternatively known as Testis-specific gene A14 protein, is required for the glutamylation of tubulin in cilia, a process vital for ciliary assembly and function. It is involved in transporting TTLL6, a key enzyme in this process, highlighting its significance in ciliogenesis.

THERAPEUTIC SIGNIFICANCE:
The involvement of the Centrosomal protein of 41 kDa in Joubert syndrome 15, a genetic disorder with symptoms ranging from cerebellar ataxia to psychomotor delay, underscores its potential as a therapeutic target. Exploring the function of this protein could lead to innovative treatments for Joubert syndrome 15, offering hope for affected individuals and their families.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.